Jurriën M. ten Berg

TL;DR: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed in collaboration with EACTS is described in this paper.

TL;DR: Use of clopiogrel without aspirin was associated with a significant reduction in bleeding complications and no increase in the rate of thrombotic events.

TL;DR: Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y12 inhibitor than amongThose who received triple therapy with warfarin, a P1Y12 inhibitors, and aspirin.

TL;DR: An updated consensus document reviews the available evidence and proposes cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy and proposes a therapeutic window concept for P2Y12 inhibitor therapy.

TL;DR: Of the platelet function tests assessed, light transmittance aggregometry, Verify Now, Platelet works, and Innovance PFA P2Y were significantly associated with the primary end point, however, the predictive accuracy of these 4 tests was only modest.